Henlius Denosumab Biosimilar Trial Enters Phase III

As Firm’s Shanghai Plant Has Received EU GMP Equivalence

 
• By Chloe Kent
Osteoporosis
The study will evaluate the impact of Henlius' candidate on bone mineral density. • Source: Shutterstock

More from Products

More from Generics Bulletin